Pandemic Darlings The pandemic economy, in original documents
Home Source documents Senate Commerce Committee Statement to Senate, No. 4259 (State of New Jersey, November 17, 2025)

Senate Commerce Committee Statement to Senate, No. 4259 (State of New Jersey, November 17, 2025)

Summary

Senate Commerce Committee statement to Senate, No. 4259 with committee amendments, State of New Jersey, dated November 17, 2025. The committee reports favorably and with committee amendments Senate Bill No. 4259, which as amended exempts insurance-support organizations and national securities associations from provisions of current law that require certain entities to notify consumers of collection and disclosure of personal data. The committee amendments include exempting national securities associations registered pursuant to section 15A of the Securities and Exchange Act of 1934, and exempting certain data, including information treated like protected health information under HIPAA. The statement says the bill is identical to Assembly Bill No. 5017 (2R).

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Senate Commerce Committee Statement to Senate, No. 4259 (State of New Jersey, November 17, 2025).” Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/2025-11-17-scm-s4259-s1-b9ce715769/, SHA-256 1a830537c889b583807ad3a7cb1629491de4d59aaa4d5901b9f6e56e2348f53a.

Full text

     SENATE COMMERCE COMMITTEE

                    STATEMENT TO

                  SENATE, No. 4259
                  with committee amendments



 STATE OF NEW JERSEY
                  DATED: NOVEMBER 17, 2025

    The Senate Commerce Committee reports favorably and with
committee amendments Senate Bill No. 4259.
   As amended, this bill exempts insurance-support organizations
and national securities associations from provisions of current law
that require certain entities to notify consumers of collection and
disclosure of personal data.          Under current law, insurance
institutions and other entities are exempt from those requirements.
   As amended, the bill exempts certain data from disclosure
requirements under current law, including:
   (1) information treated like protected health information
collected, used, or disclosed by a covered entity or business
associate under the "Health Insurance Portability and
Accountability Act of 1996" (HIPAA), when the information is
used or disclosed in accordance with HIPAA and the information is
afforded all the privacy protections and security safeguards of the
federal laws and implementing regulations under HIPAA; and
   (2) human subjects research conducted in accordance with good
clinical practice guidelines issued by The International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use.
   Finally, as amended, the bill expands the definition of de-
identified data under current law to include data de-identified in
accordance with the requirements in HIPAA, where any recipients
of that data are contractually prohibited from attempting to
reidentify the data.
   As amended and reported by the committee, Senate Bill No. 4259 is
identical to Assembly Bill No. 5017 (2R), which was also amended
and reported by the committee on this date.

COMMITTEE AMENDMENTS:
    The committee amended the bill to:
    (1) exempt national securities associations registered pursuant to
section 15A of the “Securities and Exchange Act of 1934”;
    (2) exempt certain data from disclosure requirements under current
law, including:
                                   2

    (a) information treated like protected health information collected,
used, or disclosed by a covered entity or business associate under
HIPAA, when the information is used or disclosed in accordance with
HIPAA and the information is afforded all the privacy protections and
security safeguards of the federal laws and implementing regulations
under HIPAA; and
    (b) human subjects research conducted in accordance with good
clinical practice guidelines issued by The International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use; and
    (3) expand the definition of de-identified data under current law to
include data de-identified in accordance with the requirements in
HIPAA, where any recipients of that data are contractually prohibited
from attempting to reidentify the data.

File and source

File
2025-11-17_SCM_S4259_S1.pdf
Size
139,321 bytes
SHA-256
1a830537c889b583807ad3a7cb1629491de4d59aaa4d5901b9f6e56e2348f53a
Our copy
2025-11-17_SCM_S4259_S1.pdf
Original
No public link identified.
Back to top